|
Solvent |
mg/mL |
mM |
comments |
Solubility |
DMSO |
65.5 |
162.74 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
402.49
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Saady AM, Fouad HM, Abdullatif AM, Helmy YAH, Macky TA, Mansour K. The value of prednisolone acetate provocative test before intravitreal triamcinolone acetonide injections. Eur J Ophthalmol. 2020 Jul;30(4):730-737. doi: 10.1177/1120672119842731. Epub 2019 Apr 12. PMID: 30977377.
2: KhalafAllah MT, Basiony A, Salama A. Difluprednate versus Prednisolone Acetate after Cataract Surgery: a Systematic Review and Meta-Analysis. BMJ Open. 2019 Nov 2;9(11):e026752. doi: 10.1136/bmjopen-2018-026752. PMID: 31678934; PMCID: PMC6830689.
3: Hanafy AF, Abdalla AM, Guda TK, Gabr KE, Royall PG, Alqurshi A. Ocular anti- inflammatory activity of prednisolone acetate loaded chitosan-deoxycholate self- assembled nanoparticles. Int J Nanomedicine. 2019 May 29;14:3679-3689. doi: 10.2147/IJN.S195892. PMID: 31239660; PMCID: PMC6556883.
4: Tijunelis MA, Person E, Niziol LM, Musch DC, Ernest P, McBain M, Mian SI. Comparison of prednisolone acetate 1.0% and difluprednate ophthalmic emulsion 0.05% after cataract surgery: Incidence of postoperative steroid-induced ocular hypertension. J Cataract Refract Surg. 2017 Feb;43(2):223-227. doi: 10.1016/j.jcrs.2017.02.002. PMID: 28366370.
5: Loukovaara S, Lehtinen V, Nieminen R, Moilanen J. Topical levofloxacin, nepafenac and prednisolone acetate medication after cataract surgery in the biggest tertiary eye hospital in Finland during 2015-2018. Acta Ophthalmol. 2019 Sep;97(6):e943-e945. doi: 10.1111/aos.14091. Epub 2019 Mar 27. PMID: 30916844.
6: Qiao J, Liu A, Liu J, Guan D, Chen T. Salvianolic acid B (Sal B) alleviates the decreased activity induced by prednisolone acetate on osteoblasts by up- regulation of bone formation and differentiation genes. Food Funct. 2019 Sep 1;10(9):6184-6192. doi: 10.1039/c9fo01246j. Epub 2019 Sep 10. PMID: 31501830.
7: Sheppard J, Garg S, Lievens C, Brandano L, Wirostko B, Korenfeld M, Raizman M, Foster CS. Iontophoretic Dexamethasone Phosphate Compared to Topical Prednisolone Acetate 1% for Noninfectious Anterior Segment Uveitis. Am J Ophthalmol. 2020 Mar;211:76-86. doi: 10.1016/j.ajo.2019.10.032. Epub 2019 Nov 11. PMID: 31726034.
8: Sheppard JD, Foster CS, Toyos MM, Markwardt K, Da Vanzo R, Flynn TE, Kempen JH. Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies. Ocul Immunol Inflamm. 2019;27(3):484-496. doi: 10.1080/09273948.2017.1407433. Epub 2017 Dec 20. PMID: 29260952.
9: Sousa FJ. The bioavailability and therapeutic effectiveness of prednisolone acetate vs. prednisolone sodium phosphate: a 20-year review. CLAO J. 1991 Oct;17(4):282-4. PMID: 1764775.
10: Rankin AJ, KuKanich KS, Schermerhorn T, Bello NM, Huey JA, Fentiman KE, Meekins JM. Evaluation of diabetes mellitus regulation in dogs treated with ophthalmic preparations of prednisolone acetate versus diclofenac sodium. Am J Vet Res. 2019 Dec;80(12):1129-1135. doi: 10.2460/ajvr.80.12.1129. PMID: 31763946.